Dan Caplinger

Stock shoots up.

Immediately, the company comes in and says, we're doing a secondary stock offering.

Why?

Because biotech companies constantly need money in order to finance their business, and it's a great opportunity to do it.

If, therefore...

a particular meme stock is in a business where access to capital is going to be really valuable, then responding to a big jump from a meme stock craze by selling shares and raising capital for future use, it's going to validate the value of that company.

It essentially issues shares.

It improves book value.

It improves the balance sheet.

It gives them flexibility to do things later on.

And then the question is, what are they going to do with it?

And what I want to see management do is be consistent with whatever vision they had in the past, maybe augment it by this stroke of fortune, but not get full of themselves, not let their heads get too big, just treat it for what it is.

So I was kind of surprised, you know, the headlines were talking about ASML, you know, talking about high growth.

And I was kind of like, OK, where where's the high growth?

Because the backward.

Yeah.

Down sequentially, up like low single-digit percentage year over year.

And even people were talking about positive outlook, but positive outlook, they've released 20, 30 estimates for revenue.

It implies growth rates as low as 6%.

I think the high end of the range is like closer to 13% per year.